頭頚部がん (NHC) ：市場分析、疫学、市場予測 (2032年)

2021年の主要7ヶ国における頭頚部がん (HNC) の市場規模は28億100万米ドルと観測されました。

2021年の米国における頭頚部がんの市場規模は18億3,100万米ドルでした。欧州5ヶ国のうち、2021年の市場規模が最も大きかったのはドイツで、2億1,900万米ドルでした。最も市場規模が小さいのはイタリアで、2021年は1億1,400万米ドルと推計されました。

日本では、2021年の頭頚部がんの市場規模は1億8,700万米ドルと観測されています。

米国における頭頚部がんの市場規模は、2032年までに8.2%のCAGRで成長すると予測されています。

当レポートでは、世界の主要7カ国 - 米国、欧州主要5ヶ国 (EU5：フランス・ドイツ・イタリア・スペイン・英国)、日本 - における頭頚部がん (NHC) の疫学的動向と今後の市場見通しについて分析し、疾患の概要や市場の基本構造、現在の治療法とアンメットニーズ、有病者数の動向見通し、上市済み/治験中の治療薬のプロファイル、世界全体/各国の市場規模 (2019年～2032年)、主な市場促進・抑制要因、といった情報を取りまとめてお届けいたします。

目次

第1章 主な考察

第2章 頭頚部がん (NHC)：エグゼクティブサマリー

第3章 頭頚部がん (NHC)：市場概要

• 市場シェア：治療薬別 (2019年)
• 市場シェア：治療薬別 (2032年)

第4章 頭頚部がん (HNC) - 今後の展望

第5章 頭頚部がん：エグゼクティブサマリー

第6章 主な出来事

第7章 疾患の背景と概要

• イントロダクション
• 徴候と症状
• 危険因子と病因
• 病態生理学
  • HPV陰性HNSCC
  • HPV陽性HNSCC
  • ゲノム変化と重要な経路
• 診断
• 診断ガイドライン

第8章 治療と管理

• 治療アルゴリズム
• 治療・管理のガイドライン
  • 口腔・喉頭・中咽頭・下咽頭の扁平上皮がん：EHNS-ESMO-ESTROの治療向け臨床診療ガイドライン
  • 頭頸部のSCCUP (原発不明扁平上皮がん) の管理：ASCOガイドライン
  • HNC：NCCN治療ガイドライン

第9章 調査手法

第10章 疫学と患者人口

• 主な調査結果
• 仮定と根拠：主要7ヶ国
• 頭頚部がん (NHC) の総発症件数 (主要7ヶ国の場合)
• 米国
  • 頭頚部がん (HNC) の総発症件数
  • HPV特異的頭頚部がん (HNC) の発生件数
  • 部位特異的頭頚部がん (HNC) の発症件数
  • 分子変化特異的頭頚部がん (HNC) の発症件数
  • 頭頚部がん (HNC) の発生件数：病期別
• 欧州5ヶ国
• 日本

第11章 ペイシェントジャーニー

第12章 上市済み製品

• キークロス

第13章 新規の治療薬

• キークロス競合
• 白血球インターロイキン (MULTIKINE)：CEL-SCI
  • 製品概略
  • その他の開発活動
  • 臨床開発活動
  • 安全性と有効性
• トリパリマブ：Junshi Biosciences/Coherus
• カボザンチニブ：Exelixis
• エフチラギモドアルファ (Efti/IMP321)：Immutep SAS/Merck Sharp &Dohme LLC
• LN-145 (腫瘍浸潤リンパ球)：Iovance Biotherapeutics
• ティスレリズマブ：BeiGene
• ペンプリマブ/AK105：Akeso/Chia Tai-Tianqing
• ティピファルニブ：Kura Oncology
• ゼビナパント (Debio 1143)：Merck KGaA
• ペンプリマブ/AK105：Akeso/Chia Tai-Tianqing
• ティピファルニブ：Kura Oncology
• テセントリク (アテゾリズマブ)：Hoffmann-La Roche
• Cyramza (ラムシルマブ)：Eli Lilly and Company

第14章 頭頚部がん (HNC)：主要7ヶ国の市場分析

• 分析の主なポイント
• 市場の見通し
• 属性分析
• 主要な市場予測：前提条件
• 頭頚部がん (NHC) の市場規模：主要7ヶ国
• 頭頚部がん (NHC) の市場規模：主要7ヶ国、治療薬別
• 米国の頭頚部がん (NHC) の市場規模
  • 頭頚部がん (NHC) の全体的な市場規模
  • 市場規模：治療薬別
• 欧州主要5ヶ国 (5EU) の頭頚部がん (NHC) の市場規模
• 日本の頭頚部がん (NHC) の市場規模

第15章 市場アクセスと償還

• 医療費償還
• 患者アクセスプログラム

第16章 業界の有識者 (KOL) の見解

第17章 SWOT分析

第18章 アンメットニーズ

第19章 付録

第20章 DelveInsightのサービス内容

第21章 免責事項

第22章 DelveInsightについて

List of Tables

• Table 1: Summary of Head and Neck Cancer (HNC) (2019-2032)
• Table 2: Key Events
• Table 3: Work-up for Staging and Diagnosis
• Table 4: NCCN Treatment Guidelines for HNC
• Table 5: Total Incident Cases of Head and Neck Cancer (HNC) in the 7MM (2019-2032)
• Table 6: Total Incident Cases of Head and Neck Cancer (HNC) in the United States (2019-2032)
• Table 7: HPV-specific Incident Cases of Head and Neck Cancer (HNC) in the United States (2019-2032)
• Table 8: Site-specific Incident Cases of Head and Neck Cancer (HNC) in the United States (2019-2032)
• Table 9: Molecular Alteration-specific Incident Cases of Head and Neck Cancer (HNC) in the United States (2019-2032)
• Table 10: Stage-specific Incident Cases of Head and Neck Cancer (HNC) in the United States (2019-2032)
• Table 11: Total Incident Cases of Head and Neck Cancer (HNC) in the EU-5 (2019-2032)
• Table 12: HPV-specific Incident Cases of Head and Neck Cancer (HNC) in the EU-5 (2019-2032)
• Table 13: Site-specific Incident Cases of Head and Neck Cancer (HNC) in the EU-5 (2019-2032)
• Table 14: Molecular Alteration-specific Incident Cases of Head and Neck Cancer (HNC) in the EU-5 (2019-2032)
• Table 15: Stage-specific Incident Cases of Head and Neck Cancer (HNC) in the EU-5 (2019-2032)
• Table 16: Total Incident Cases of Head and Neck Cancer (HNC) in Japan (2019-2032)
• Table 17: HPV-specific Incident Cases of Head and Neck Cancer (HNC) in Japan (2019-2032)
• Table 18: Site-specific Incident Cases of Head and Neck Cancer (HNC) in Japan (2019-2032)
• Table 19: Molecular Alteration-specific Incident Cases of Head and Neck Cancer (HNC) in Japan (2019-2032)
• Table 20: Stage-specific Incident Cases of Head and Neck Cancer (HNC) in Japan (2019-2032)
• Table 21: ERBITUX (Cetuximab), Clinical Trial Description, 2022
• Table 22: Efficacy Results in Locoregionally Advanced SCCHN in BONNER
• Table 23: Efficacy Results in Recurrent Locoregional Disease or Metastatic SCCHN in EXTREME
• Table 24: OPDIVO (nivolumab), Clinical Trial Description, 2022
• Table 25: OS-CheckMate 141
• Table 26: KEYTRUDA (pembrolizumab), Clinical Trial Description, 2022
• Table 27: Efficacy Results* for KEYTRUDA Plus Platinum/Fluorouracil in KEYNOTE-048
• Table 28: Efficacy Results* for KEYTRUDA as a Single Agent in KEYNOTE-048 (CPS ≥1 and CPS ≥20)
• Table 29: Key cross competition
• Table 30: Leukocyte Interleukin (MULTIKINE), Clinical Trial Description, 2022
• Table 31: Toripalimab, Clinical Trial Description, 2022
• Table 32: Cabozantinib, Clinical Trial Description, 2022
• Table 33: Eftilagimod alpha (Efti/IMP321), Clinical Trial Description, 2022
• Table 34: LN-145, Clinical Trial Description, 2022
• Table 35: Tislelizumab, Clinical Trial Description, 2022
• Table 36: Penpulimab/AK105, Clinical Trial Description, 2022
• Table 37: Tipifarnib, Clinical Trial Description, 2022
• Table 38: XEVINAPANT (Debio 1143), Clinical Trial Description, 2022
• Table 39: AN2025 (buparlisib), Clinical Trial Description, 2022
• Table 40: LENVIMA (MK-7902/Lenvatinib), Clinical Trial Description, 2022
• Table 41: TECENTRIQ (Atezolizumab), Clinical Trial Description, 2022
• Table 42: Cyramza (ramucircumab), Clinical Trial Description, 2022
• Table 43: Key Market Forecast Assumptions for ERBITUX (cetuximab)
• Table 44: Key Market Forecast Assumptions for OPDIVO (nivolumab)
• Table 45: Key Market Forecast Assumptions for KEYTRUDA (pembrolizumab)
• Table 46: Key Market Forecast Assumptions for leukocyte interleukin (MULTIKINE)
• Table 47: Key Market Forecast Assumptions for toripalimab
• Table 48: Key Market Forecast Assumptions for cabozantinib
• Table 49: Key Market Forecast Assumptions for Eftilagimod alpha (efti/IMP321)
• Table 50: Key Market Forecast Assumptions for LN-145
• Table 51: Key Market Forecast Assumptions for tislelizumab (BGB-A317)
• Table 52: Key Market Forecast Assumptions for penpulimab
• Table 53: Key Market Forecast Assumptions for tipifarnib
• Table 54: Key Market Forecast Assumptions for Xevinapant (debio 1143)
• Table 55: Key Market Forecast Assumptions for AN2025 (buparlisib)
• Table 56: Key Market Forecast Assumptions for LENVIMA (MK-7902/lenvatinib)
• Table 57: Key Market Forecast Assumptions for TECENTRIQ (atezolizumab)
• Table 58: Key Market Forecast Assumptions for CYRAMZA (ramucirumab)
• Table 59: Key Market Forecast Assumptions for CYRAMZA (ramucirumab)
• Table 60: Seven Major Market Size of Head and Neck Cancer (HNC), USD Million (2019-2032)
• Table 61: Market Size of Head and Neck Cancer (HNC) by Therapies in the 7MM, USD Million (2019-2032)
• Table 62: Total Market Size of Head and Neck Cancer (HNC) in the United States, USD Millions (2019-2032)
• Table 63: Market Size of Head and Neck Cancer (HNC) by Therapies in the United States, USD Million (2019-2032)
• Table 64: Market Size of Head and Neck Cancer (HNC) by Therapies (Adjuvant/Neo-adjuvant) in the United States, USD Million (2019-2032)
• Table 65: Market Size of Head and Neck Cancer (HNC) by Therapies in the United States (First-line), in USD Million (2019-2032)
• Table 66: Market Size of Head and Neck Cancer (HNC) Cancer by Therapies (Second-line plus) in the United States, USD Million (2019-2032)
• Table 67: Total Market Size of Head and Neck Cancer (HNC) in EU-5, USD Million (2019-2032)
• Table 68: Market Size of Head and Neck Cancer (HNC) by therapies in EU-5, in USD Million (2019-2032)
• Table 69: Market size of Head and Neck Cancer (HNC) by therapies (Adjuvant/Neo-adjuvant) in EU-5, USD Million (2019-2032)
• Table 70: Market Size of Head and Neck Cancer (HNC) by Therapies (First-line) in EU-5, USD Million (2019-2032)
• Table 71: Market Size of Head and Neck Cancer (HNC) by Therapies (Second-line plus) in EU-5, USD Million (2019-2032)
• Table 72: Total Market Size of Head and Neck Cancer (HNC) in Japan, USD Millions (2019-2032)
• Table 73: Market Size of Head and Neck Cancer (HNC) by Therapies in Japan, USD Million (2019-2032)
• Table 74: Market size of Head and Neck Cancer (HNC) by Therapies (Adjuvant/Neo-adjuvant) in Japan, USD Million (2019-2032)
• Table 75: Market size of Head and Neck Cancer (HNC) by Therapies in Japan (First-line), USD Million (2019-2032)
• Table 76: Market size of Head and Neck Cancer (HNC) by therapies in Japan (Second-line plus), in USD Million (2019-2032)

List of Figures

• Figure 1: HNC Regions
• Figure 2: Symptoms of HNC
• Figure 3: Progression of HNSCC and key Genetic Events
• Figure 4: Development of Carcinogen-associated, HPV-negative HNSCC
• Figure 5: HPV Infection of the Tonsil Crypt and Development of HPV-positive HNSCC
• Figure 6: Treatment Options in Locally Advanced SCCHN (SEOM Clinical Guidelines)
• Figure 7: Algorithm for Treatment Decision-making for Recurrent and/or Metastatic HNSCC
• Figure 8: Proposed Treatment Algorithm in the First-line Setting for Patients With Recurrent and/or Metastatic HNSCC
• Figure 9: Proposed Treatment Algorithm in the Second-line Setting for Patients With Recurrent and/or Metastatic HNSCC
• Figure 10: Proposed Treatment Algorithm for Recurrent and/or Metastatic HNSCC Patients After Exposure to First-line Immunotherapy +/- Chemotherapy
• Figure 11: Total Incident Cases of Head and Neck Cancer (HNC) in the 7MM (2019-2032)
• Figure 12: Total Incident Cases of Head and Neck Cancer (HNC) in the United States (2019-2032)
• Figure 13: HPV-specific Incident Cases of Head and Neck Cancer (HNC) in the United States (2019-2032)
• Figure 14: Site-specific Incident Cases of Head and Neck Cancer (HNC) in the United States (2019-2032)
• Figure 15: Molecular Alteration-specific Incident Cases of Head and Neck Cancer (HNC) in the United States (2019-2032)
• Figure 16: Stage-specific Incident Cases of Head and Neck Cancer (HNC) in the United States (2019-2032)
• Figure 17: Total Incident Cases of Head and Neck Cancer (HNC) in EU-5 (2019-2032)
• Figure 18: HPV-specific Incident Cases of Head and Neck Cancer (HNC) in EU-5 (2019-2032)
• Figure 19: Site-specific Incident Cases of Head and Neck Cancer (HNC) in EU-5 (2019-2032)
• Figure 20: Molecular Alteration-specific Incident Cases of Head and Neck Cancer (HNC) in EU-5 (2019-2032)
• Figure 21: Stage-specific Incident Cases of Head and Neck Cancer (HNC) in EU-5 (2019-2032)
• Figure 22: Total Incident Cases of Head and Neck Cancer (HNC) in Japan (2019-2032)
• Figure 23: HPV-specific Incident Cases of Head and Neck Cancer (HNC) in Japan (2019-2032)
• Figure 24: Site-specific Incident Cases of Head and Neck Cancer (HNC) in Japan (2019-2032)
• Figure 25: Molecular Alteration-specific Incident Cases of Head and Neck Cancer (HNC) in Japan (2019-2032)
• Figure 26: Stage-specific Incident Cases of Head and Neck Cancer (HNC) in Japan (2019-2032)
• Figure 27: Kaplan-Meier Curves for OS in Patients with Recurrent Locoregional Disease or Metastatic SCCHN in EXTREME
• Figure 28: OS-CheckMate 141
• Figure 29: Kaplan-Meier Curve for OS for KEYTRUDA plus
• Figure 30: Kaplan-Meier Curve for OS for KEYTRUDA as
• Figure 31: Baseline Demographic and Clinical Characteristics and Efficacy
• Figure 32: Market Size of Head and Neck Cancer (HNC), USD Millions (2019-2032)
• Figure 33: Market Size of Head and Neck Cancer (HNC) by Therapies in the 7MM, USD Millions (2019-2032)
• Figure 34: Total Market Size of Head and Neck Cancer (HNC) in the United States, USD Millions (2019-2032)
• Figure 35: Market Size of Head and Neck Cancer (HNC) by Therapies in the United States, USD Million (2019-2032)
• Figure 36: Market Size of Head and Neck Cancer (HNC) by Therapies (Adjuvant/Neo-adjuvant) in the United States, USD Million (2019-2032)
• Figure 37: Market Size of Head and Neck Cancer (HNC) by Therapies (First-line) in the United States, USD Million (2019-2032)
• Figure 38: Market Size of Head and Neck Cancer (HNC) by Therapies (Second-line plus) in the United States, in USD Million (2019-2032)
• Figure 40: Market Size of Head and Neck Cancer (HNC) by Therapies in EU-5, USD Million (2019-2032)
• Figure 41: Market size of Head and Neck Cancer (HNC) by Therapies (Adjuvant/Neo-adjuvant) in EU-5, USD Million (2019-2032)
• Figure 42: Market Size of Head and Neck Cancer (HNC) by Therapies (First-line) in EU-5, USD Million (2019-2032)
• Figure 43: Market Size of Head and Neck Cancer (HNC) by Therapies (Second-line plus) in EU-5, USD Million (2019-2032)
• Figure 44: Total Market Size of Head and Neck Cancer (HNC) in Japan, USD Millions (2019-2032)
• Figure 45: Market Size of Head and Neck Cancer (HNC) by Therapies in Japan, USD Million (2019-2032)
• Figure 46: Market size of Head and Neck Cancer (HNC) by Therapies (Adjuvant/Neo-adjuvant) in Japan, USD Million (2019-2032)
• Figure 47: Market size of Head and Neck Cancer (HNC) by Therapies in Japan (First-line), USD Million (2019-2032)
• Figure 48: Market Size of Head and Neck Cancer (HNC) by Therapies (Second-line plus) in Japan, USD Million (2019-2032)
• Figure 49: Unmet needs

DelveInsight's 'Head and Neck Cancer (HNC) - Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the Head and neck cancer (HNC) historical and forecasted epidemiology as well as the Head and neck cancer (HNC) cancer market trends in the United States, EU-5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The Head and Neck Cancer (HNC) market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Head and neck cancer (HNC) market size. The report also covers current Head and neck cancer (HNC) treatment practice, SWOT analysis, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered:

• The United States

• EU-5 (Germany, France, Italy, Spain, and the United Kingdom)

• Japan

Study Period: 2019-2032.

Head and Neck Cancer (HNC) Disease Understanding and Treatment

Head and Neck Cancer (HNC) Cancer Overview

HNC refers to several types of cancers that affect the head and neck areas of the body. These cancers account for approximately 3-5% of all cancers in the US and are common in men and people over the age of 50. These cancers are easily preventable and can be treated if diagnosed early. The most common causes of HNC are tobacco and alcohol use, and nowadays, HPV has also emerged as an important risk factor. HNC usually begins in the squamous cells - often referred to as squamous cell carcinomas of the head and neck - that line the mucosal surfaces of the head and neck for example, those inside the mouth, throat, and voice box. They can also begin in the salivary glands, sinuses, muscles, or nerves, but they are less common than squamous cell carcinomas.

Continued in the report…

Head and Neck Cancer Diagnosis

There are many tests used for diagnosing HNC. The doctor may consider these factors when choosing a diagnostic test:

• The type of cancer suspected
• Signs and symptoms
• Age and general health
• The results of earlier medical tests

If a person has symptoms and signs of HNC, the doctor will take a complete medical history, noting all symptoms and risk factors. In addition, the following tests may be used to diagnose HNC:

Physical examination/blood and urine tests

During a physical examination, the doctor feels for any lumps on the neck, lips, gums, and cheeks. The doctor will also inspect the nose, mouth, throat, and tongue for abnormalities, often using a light and a mirror for a clearer view. Blood tests and urine tests may be done to help diagnose cancer.

Endoscopy

An endoscopy allows the doctor to see inside the body with a thin, lighted, flexible tube called an endoscope. The person may be sedated as the tube is gently inserted through the nose into the throat and down the esophagus to examine the head and neck.

Biopsy

A biopsy removes a small amount of tissue for examination under a microscope. A pathologist then analyzes the sample(s) removed during the biopsy. A common type of biopsy is called fine needle aspiration. This procedure collects cells using a thin needle inserted directly into the tumor or lymph node. The cells are examined under a microscope for cancer cells, called a cytologic examination.

Biomarker testing of the tumor

The doctor may recommend running laboratory tests on a tumor sample to identify specific genes, proteins, and other factors unique to the tumor; also called molecular testing of the tumor, these tests help determine the treatment options.

Continued in the report…

Head and Neck Cancer Treatment

The main treatment options are surgery, radiation therapy, chemotherapy, targeted therapy, and immunotherapy. Surgery, radiation therapy, or a combination of these treatments are part of the treatment plan.

Surgery

During surgery, the goal is to remove the cancerous tumor and some surrounding healthy tissue during an operation. Types of surgery for HNC include:

• Laser technology - This may be used to treat an early-stage tumor, especially if found in the larynx

• Excision - This is an operation to remove the cancerous tumor and some surrounding healthy tissue, known as a margin

• Lymph node dissection or neck dissection - If the doctor suspects cancer has spread, the doctor may remove lymph nodes in the neck. This may be done at the same time as an excision

• Reconstructive (plastic) surgery - If cancer surgery requires major tissue removal, such as removing the jaw, skin, pharynx, or tongue, reconstructive or plastic surgery may be done to replace the missing tissue.

Continued in the report…..

Head and Neck Cancer Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Incident Cases of Head and Neck Cancer, Molecular Alteration-specific Incident Cases of Head and Neck Cancer, and Stage-specific Incident Cases of Head and Neck Cancer, Site-specific Incident Cases of Head and Neck Cancer, HPV-specific Incident Cases of Head and Neck Cancer scenario in the 7MM covering the United States, EU-5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.

Key Findings

• In 2021, the total incident cases of HNC in the 7MM countries were ~158,000, and these cases are anticipated to increase during the study period.

• Among the European countries, Germany had the highest number of incident cases of HNC in 2021, i.e., ~20,000 cases, followed by France which had ~16,000 incident cases in 2021. On the other hand, Italy had the lowest incident cases of HNC, i.e. ~9900 cases in 2021. Japan had ~20,000 incident cases of HNC in 2021.

• The analysis from 2021 suggests that the stage-specific incident cases of Head and Neck Cancer (HNC) in the US were maximum for regional, at ~30,000 cases, followed by localized with ~21,000 cases, distant with ~11,000 cases, and ~3,000 cases of the unknown stage.

• In 2021, the molecular alteration-specific incident cases of HNC in the US were maximum for TP53 at ~47,000 cases followed by CCND1, PIK3CA, NOTCH1, KMT2D, EGFR, NSD1, FGFR1, and HRAS mutations that had ~18,000 cases; ~14,000 cases; ~12,400 cases; ~12,000 cases; ~10,000 cases; ~6,500 cases; ~5,700 cases; and ~3,300 cases respectively.

• In 2021, the HPV status-specific incident cases of Head and Neck Cancer (HNC) in the US were maximum for HPV negative at ~40,000 cases followed by HPV positive at ~23,000 cases. By 2032, HPV status-specific incident cases of HNC are expected to increase significantly.

Head and Neck Cancer Epidemiology

The epidemiology segment provides the Head and Neck Cancer epidemiology data and findings across the United States, EU-5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Head and Neck Cancer Drug Chapters

Head and Neck Cancer Emerging Drugs

TECENTRIQ (Atezolizumab): Hoffmann-La Roche

TECENTRIQ (Atezolizumab) is an engineered monoclonal antibody that targets the ligand PD-L1 (programmed death ligand 1) and aims to prevent cancer immune evasion. A Phase III trial evaluates TECENTRIQ in patients with adjuvant SCCHN (Roche, 2022). Atezolizumab binds to PD-L1 and blocks its interactions with both PD-1 and B7 receptors. This releases the PD-L1/PD-1 mediated inhibition of the immune response, including activation of the anti-tumor immune response without inducing antibody-dependent cellular cytotoxicity (Genentech, 2022). It is under clinical development to treat locally advanced SCCHN as adjuvant therapy.

Products detail in the report…

KEYTRUDA (pembrolizumab): Merck Sharp & Dohme

KEYTRUDA (pembrolizumab) is an anti-programmed death receptor-1 (PD-1) therapy that works by increasing the ability of the body's immune system to help detect and fight tumor cells. A humanized monoclonal antibody blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby activating T lymphocytes which may affect tumor cells and healthy cells. KEYTRUDA is indicated for HNSCC in combination with platinum and fluorouracil (FU) for the first-line treatment of patients with metastatic or unresectable, recurrent HNSCC. As a single agent for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test, and as a single agent for the treatment of patients with recurrent or metastatic HNSCC with disease progression on or after platinum-containing chemotherapy.

Products detail in the report…

XEVINAPANT (debio 1143): Merck KGaA

XEVINAPANT (debio 1143) is a potential first-in-class potent oral antagonist of IAPs (Inhibitor of Apoptosis Proteins) being investigated in the Phase III TrilynX study for previously untreated high-risk locally advanced LA SCCHN, in combination with platinum-based chemotherapy and standard fractionation intensity-modulated radiotherapy. It prevents the programmed cell death caused by chemoradiotherapy (CRT) and is believed to deprive tumors of one of their major resistance mechanisms, thereby increasing tumor cell sensitivity to CRT.

Products detail in the report…

Toripalimab: Junshi Biosciences/Coherus

Toripalimab is an anti-PD-1 monoclonal antibody developed to block PD-1 interactions with its ligands, PD-L1, and PD-L2, and for enhanced receptor endocytosis function. PD-L1 and PD-L2 are tumor checkpoint proteins that recognize the PD-1 receptor on T-cell and exhaust their anti-tumor activity. Blocking PD-1 interactions with PD-L1 and PD-L2 is thought to recharge the immune system's ability to attack and kill tumor cells.

Products detail in the report…

Tipifarnib: Kura Oncology

Kura Oncology's lead drug candidate, tipifarnib, is a potent and highly selective inhibitor of farnesylation, a key cell signaling process in cancer initiation and development. Tipifarnib has been studied in more than 5,000 cancer patients and showed compelling and durable anti-cancer activity in certain patient subsets, however, no molecular mechanism of action had previously been determined that could explain its activity across a range of diverse clinical indications, including squamous tumors that carry mutant HRAS, as well as in lymphoid, myeloid and solid tumors that do not carry HRAS mutations.

Products detail in the report…

List to be continued in the report…

Head and Neck Cancer Market Outlook

HNC is a broad indication involving many site-specific cancers, such as laryngeal and hypopharyngeal cancer, nasal cavity and par nasal sinus cancer, nasopharyngeal cancer, oral and or pharyngeal cancer, and salivary gland cancer. Many cancers of the head and neck are curable, especially if detected at an early stage. Although eliminating the cancer is the primary goal of treatment, preserving the function of the nearby nerves, organs, and tissues is also very important. When planning treatment, doctors consider how treatment might affect a person's quality of life, such as how a person feels, looks, talks, eats, and breathes.

Overall, the treatment approach for HNC patients can involve multiple options like surgery, radiation therapy, chemotherapy, targeted therapy, and immunotherapy. Pharmacological therapies are mainly used to destroy cancer cells, and they are either administered systematically or locally (by a medical oncologist). Pharmacological therapies being administered to a HNC patient can be chemotherapy, targeted therapy, or immunotherapy.

The HNSCC is the sixth most common cancer worldwide. Over 50% of patients with HNSCC are diagnosed with loco regionally advanced (Stage III) disease, whereas newly diagnosed metastatic HNSCC (Stage IVc) is uncommon (4% of newly diagnosed HNSCC). Patients with locoregionally advanced HNSCC typically receive multimodal treatment using surgery or radiation with or without chemotherapy.

Among all the available therapeutic options, chemotherapy is being extensively used in all lines of treatment. Multiple drugs have been identified with the advancement of medical technologies and increased research and development activities. Immunotherapeutic options have also been identified for treating HNC patients.

Continued in the report…..

Key Findings

• The market size of Head and Neck Cancer in the 7MM was observed to be of USD 2,801 million in 2021.

• In 2021, the market size of Head and Neck Cancer in the US was of USD 1,831 million. Among the EU-5 countries, Germany had the highest market size for Head and Neck Cancer in 2021, i.e., USD 219 million. The lowest market size was estimated in Italy with USD 114 million in 2021.

• In Japan, the market size of Head and Neck Cancer was observed to be of USD 187 million in 2021.

• The market size of Head and Neck Cancer in The United States will grow at a CAGR of 8.2% by 2032.

The United States Market Outlook

This section provides the total Head and Neck Cancer market size and market size by therapies in the United States.

EU-5 Market Outlook

The total Head and Neck Cancer market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

Japan Market Outlook

The total Head and Neck Cancer market size and market size by therapies in Japan are provided.

Head and Neck Cancer Drugs Uptake

This section focuses on the rate of uptake of the potential drugs recently launched in the Head and Neck Cancer market or expected to get launched in the market during the study period 2019-2032. The analysis covers the Head and Neck Cancer market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Head and Neck Cancer Development Activities

The report provides insights into different therapeutic candidates in Phase II and Phase III stage. It also analyzes key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for Head and Neck Cancer emerging therapies.

Reimbursement Scenario in Head and Neck Cancer

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In the report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

Competitive Intelligence Analysis

We perform competitive market Intelligence analysis of the Head and Neck Cancer market by using various competitive intelligence tools that include-SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report:

• The report covers the descriptive overview of Head and Neck Cancer, explaining its causes, symptoms, pathophysiology, genetic basis, diagnosis, and currently available therapies.

• Comprehensive insight has been provided into the Head and Neck Cancer epidemiology and treatment.

• Additionally, an all-inclusive account of both the current and emerging therapies for Head and Neck Cancer is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.

• A detailed review of the Head and Neck Cancer market; historical and forecasted is included in the report, covering the 7MM drug outreach.

• The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM Head and Neck Cancer market.

Report Highlights:

• The robust pipeline with novel MOA and oral ROA, increasing prevalence, and effectiveness of drugs will positively drive the Head and Neck Cancer market.

• The companies and academics are working to assess challenges and seek opportunities that could influence Head and Neck Cancer R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.

• Major players are involved in developing therapies for Head and Neck Cancer. The launch of emerging therapies will significantly impact the Head and Neck Cancer market.

• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Head and Neck Cancer Report Insights

• Patient Population
• Therapeutic Approaches
• Head and Neck Cancer Pipeline Analysis
• Head and Neck Cancer Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies

Head and Neck Cancer Report Key Strengths

• 11 Years Forecast
• 7MM Coverage
• Head and Neck Cancer Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Market
• Drugs Uptake

Head and Neck Cancer Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• SWOT analysis

Key Questions

Market Insights:

• What was the Head and Neck Cancer market share (%) distribution in 2019 and how it would look like in 2032?

• What would be the Head and Neck Cancer total market size as well as market size by therapies across the 7MM during the forecast period (2022-2032)?

• What are the key findings pertaining to the market across the 7MM and which country will have the largest Head and Neck Cancer market size during the forecast period (2022-2032)?

• At what CAGR, the Head and Neck Cancer market is expected to grow at the 7MM level during the forecast period (2022-2032)?

• What would be the Head and Neck Cancer market outlook across the 7MM during the forecast period (2022-2032)?

• What would be the Head and Neck Cancer market growth till 2032 and what will be the resultant market size in the year 2032?

• How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

• What are the disease risk, burdens, and unmet needs of Head and Neck Cancer?

• What is the historical Head and Neck Cancer patient pool in the United States, EU-5 (Germany, France, Italy, Spain, and the UK), and Japan?

• What would be the forecasted patient pool of Head and Neck Cancer at the 7MM level?

• What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Head and Neck Cancer?

• Out of the above-mentioned countries, which country would have the highest population of Head and Neck Cancer during the forecast period (2022-2032)?

• At what CAGR the population is expected to grow across the 7MM during the forecast period (2022-2032)?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

• What are the current options for the treatment of Head and Neck Cancer along with the approved therapy?

• What are the current treatment guidelines for the treatment of Head and Neck Cancer?

• What are the Head and Neck Cancer marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?

• How many companies are developing therapies for the treatment of Head and Neck Cancer?

• How many emerging therapies are in the mid-stage and late stages of development for the treatment of Head and Neck Cancer?

• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Head and Neck Cancer therapies?

• What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?

• What are the clinical studies going on for Head and Neck Cancer and their status?

• What are the key designations that have been granted for the emerging therapies for Head and Neck Cancer?

• What are the 7MM historical and forecasted market of Head and Neck Cancer?

Reasons to buy:

• The report will help in developing business strategies by understanding trends shaping and driving Head and Neck Cancer.

• To understand the future market competition in the Head and Neck Cancer market and an insightful review of the market.

• Organize sales and marketing efforts by identifying the best opportunities for Head and Neck Cancer in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.

• Organize sales and marketing efforts by identifying the best opportunities for the Head and Neck Cancer market.

• To understand the future market competition in the Head and Neck Cancer market.

Table of Contents

1. Key Insights

2. Report Introduction

3. Head and Neck Cancer (HNC) -Market Overview at a Glance

• 3.1. Market Share (%) Head and Neck Cancer (HNC) by Therapies in 2019
• 3.2. Market Share (%) of Head and Neck Cancer (HNC) by Therapies in 2032

4. Head and Neck Cancer (HNC) - Future Prospects

5. Executive Summary of Head and Neck Cancer

• 5.1. Quick Insights

6. Key Events

7. Disease Background and Overview

• 7.1. Introduction
• 7.2. Signs and Symptoms
• 7.3. Risk Factors and Causes
• 7.4. Pathophysiology
  • 7.4.1. HPV-negative HNSCC
  • 7.4.2. HPV-positive HNSCC
  • 7.4.3. Genomic alterations and key pathways
• 7.5. Diagnosis
• 7.6. Diagnostic Guidelines
  • 7.6.1. Squamous cell carcinoma of the oral cavity, larynx, oropharynx, and hypopharynx: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis
  • 7.6.2. Diagnosis of Squamous Cell Carcinoma of Unknown Primary (SCCUP) in the head and neck: ASCO Guideline

8. Treatment and Management

• 8.1. Treatment Algorithms
• 8.2. Treatment and Management Guidelines
  • 8.2.1. Squamous cell carcinoma of the oral cavity, larynx, oropharynx, and hypopharynx: EHNS-ESMO-ESTRO Clinical Practice Guidelines for treatment
  • 8.2.2. Management of Squamous Cell Carcinoma of Unknown Primary (SCCUP) in the head and neck: ASCO Guideline
  • 8.2.3. HNC: NCCN Treatment Guidelines

9. Methodology

10. Epidemiology and Patient Population

• 10.1. Key Findings
• 10.2. Assumptions and Rationale 7MM
• 10.3. Total Incident Cases of Head and Neck Cancer (HNC) in the 7MM
• 10.4. The United States
  • 10.4.1. Total Incident Cases of Head and Neck Cancer (HNC) in the United States
  • 10.4.2. HPV-specific Incident Cases of Head and Neck Cancer (HNC) in the United States
  • 10.4.3. Site-specific Incident Cases of Head and Neck Cancer (HNC) in the United States
  • 10.4.4. Molecular Alteration-specific Incident Cases of Head and Neck Cancer (HNC) in the United States
  • 10.4.5. Stage-specific Incident Cases of Head and Neck Cancer (HNC) in the United States
• 10.5. EU-5
  • 10.5.1. Total Incident Cases of Head and Neck Cancer (HNC) in the EU-5
  • 10.5.2. HPV-specific Incident Cases of Head and Neck Cancer (HNC) in the EU-5
  • 10.5.3. Site-specific Incident Cases of Head and Neck Cancer (HNC) in the EU-5
  • 10.5.4. Molecular Alteration-specific Incident Cases of Head and Neck Cancer (HNC) in the EU-5
  • 10.5.5. Stage-specific Incident Cases of Head and Neck Cancer (HNC) in the EU-5
• 10.6. Japan
  • 10.6.1. Total Incident Cases of Head and Neck Cancer (HNC) in Japan
  • 10.6.2. HPV-specific Incident Cases of Head and Neck Cancer (HNC) in Japan
  • 10.6.3. Site-specific Incident Cases of Head and Neck Cancer (HNC) in Japan
  • 10.6.4. Molecular Alteration-specific Incident Cases of Head and Neck Cancer (HNC) in Japan
  • 10.6.5. Stage-specific Incident Cases of Head and Neck Cancer (HNC) in Japan

11. Patient Journey

12. Marketed Products

• 12.1. Key-cross

13. Emerging Therapies

• 13.1. Key Cross Competition
• 13.2. Leukocyte Interleukin (MULTIKINE): CEL-SCI
  • 13.2.1. Product description
  • 13.2.2. Other developmental activities
  • 13.2.3. Clinical developmental activities
    • 13.2.3.1. Clinical trials information
  • 13.2.4. Safety and efficacy
• 13.3. Toripalimab: Junshi Biosciences/Coherus
  • 13.3.1. Product description
  • 13.3.2. Other developmental activities
  • 13.3.3. Clinical developmental activities
    • 13.3.3.1. Clinical trials information
  • 13.3.4. Safety and efficacy
• 13.4. Cabozantinib: Exelixis
  • 13.4.1. Product description
  • 13.4.2. Clinical developmental activities
    • 13.4.2.1. Clinical trials information
  • 13.4.3. Safety and efficacy
• 13.5. Eftilagimod alpha (Efti/IMP321): Immutep S.A.S./Merck Sharp & Dohme LLC
  • 13.5.1. Product description
  • 13.5.2. Other developmental activities
  • 13.5.3. Clinical developmental activities
    • 13.5.3.1. Clinical trials information
  • 13.5.4. Safety and efficacy
• 13.6. LN-145 (Tumor Infiltrating Lymphocytes): Iovance Biotherapeutics
  • 13.6.1. Product description
  • 13.6.2. Clinical developmental activities
    • 13.6.2.1. Clinical trials information
  • 13.6.3. Safety and efficacy
• 13.7. Tislelizumab: BeiGene
  • 13.7.1. Product description
  • 13.7.2. Other developmental activities
  • 13.7.3. Clinical developmental activities
    • 13.7.3.1. Clinical trials information
  • 13.7.4. Safety and efficacy
• 13.8. Penpulimab/AK105: Akeso/Chia Tai-Tianqing
  • 13.8.1. Product description
  • 13.8.2. Other developmental activities
  • 13.8.3. Clinical developmental activities
    • 13.8.3.1. Clinical trials information
  • 13.8.4. Safety and efficacy
• 13.9. Tipifarnib: Kura Oncology
  • 13.9.1. Product description
  • 13.9.2. Other developmental activities
  • 13.9.3. Clinical developmental activities
    • 13.9.3.1. Clinical trials information
  • 13.9.4. Safety and efficacy
• 13.10. XEVINAPANT (Debio 1143): Merck KGaA
  • 13.10.1. Product description
  • 13.10.2. Other developmental activities
  • 13.10.3. Clinical developmental activities
    • 13.10.3.1. Clinical trials information
  • 13.10.4. Safety and efficacy
• 13.11. Penpulimab/AK105: Akeso/Chia Tai-Tianqing
  • 13.11.1. Product description
  • 13.11.2. Other developmental activities
  • 13.11.3. Clinical developmental activities
    • 13.11.3.1. Clinical trials information
  • 13.11.4. Safety and efficacy
• 13.12. Tipifarnib: Kura Oncology
  • 13.12.1. Product description
  • 13.12.2. Other developmental activities
  • 13.12.3. Clinical developmental activities
    • 13.12.3.1. Clinical trials information
  • 13.12.4. Safety and efficacy
• 13.13. TECENTRIQ (atezolizumab): Hoffmann-La Roche
  • 13.13.1. Product description
  • 13.13.2. Clinical developmental activities
    • 13.13.2.1. Clinical trials information
  • 13.13.3. Safety and efficacy
• 13.14. Cyramza (ramucirumab): Eli Lilly and Company
  • 13.14.1. Product description
  • 13.14.2. Other developmental activities
  • 13.14.3. Clinical developmental activities
    • 13.14.3.1. Clinical trials information
  • 13.14.4. Safety and efficacy

14. Head and Neck Cancer (HNC): Seven Major Market Analysis

• 14.1. Key Findings
• 14.3. Market Outlook
• 14.4. Attribute Analysis
• 14.5. Key Market Forecast Assumptions
• 14.6. Market size of Head and Neck Cancer (HNC) in the 7MM
• 14.7. Market size of Head and Neck Cancer (HNC) Cancer by Therapies in the 7MM
• 14.8. Market size of Head and Neck Cancer (HNC) in the United States
  • 14.8.1. Total Market size of Head and Neck Cancer (HNC)
  • 14.8.2. Market Size of Head and Neck Cancer (HNC) by Therapies
    • 14.8.2.1. Market Size of Head and Neck Cancer (HNC) by Therapies (Adjuvant/Neo-adjuvant) in the United States
    • 14.8.2.2. Market Size of Head and Neck Cancer (HNC) by Therapies (First-line) in the United States
    • 14.8.2.3. Market Size of Head and Neck Cancer (HNC) by Therapies (Second-line plus) in the United States
• 14.9. Market Size of Head and Neck Cancer (HNC) in EU-5
  • 14.9.1. Total Market Size of Head and Neck Cancer (HNC)
  • 14.9.2. Market Size of Head and Neck Cancer (HNC) by Therapies
    • 14.9.2.1. Market Size of Head and Neck Cancer (HNC) by Therapies (Adjuvant/Neo-adjuvant) in EU-5
    • 14.9.2.2. Market Size of Head and Neck Cancer (HNC) by Therapies (First-line) in EU-5
    • 14.9.2.3. Market Size of Head and Neck Cancer (HNC) by Therapies (Second-line plus) in EU-5
• 14.10. Market Size of Head and Neck Cancer (HNC) in Japan
  • 14.10.1. Total Market Size of Head and Neck Cancer (HNC)
  • 14.10.2. Market Size of Head and Neck Cancer (HNC) by Therapies
    • 14.10.2.1. Market Size of Head and Neck Cancer (HNC) by Therapies (Adjuvant/Neo-adjuvant) in Japan
    • 14.10.2.2. Market Size of Head and Neck Cancer (HNC) by Therapies (First-line) in Japan
    • 14.10.2.3. Market Size of Head and Neck Cancer (HNC) by Therapies (Second-line plus) in Japan

15. Market Access and Reimbursement

• 15.1. Reimbursement
• 15.2. Patient Access Program

16. KOL Views

17. SWOT Analysis

18. Unmet Needs

19. Appendix

• 19.1. Report Methodology
• 19.2. Bibliography

20. DelveInsight Capabilities

21. Disclaimer

22. About DelveInsight